Laurus Labs receive ANDA approval; stock shines

Laurus Labs today informed the bourses that it has received an approval from USFDA under President’s Emergency Plan for AIDS Relief (PEPFAR) for two abbreviated new drug applications (ANDAs) TLE 400 (Tenofovir/ Lamivudine/Efavirenz- 300/300/400 mg) and TLE 600 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/600 mg) tablets.

Laurus Labs is one of the few players in the ARV segment to receive an approval for TLE 400 tablets. TLE 400 is one of the most preferred regimens in the ARV first line treatment. The company has already received WHO pre-qualification for TLE 400 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/400 mg).

With these approvals, the company can launch both the products in several LMIC markets. 

Laurus Labs is a leading research driven pharmaceutical manufacturing company in India. It is one of the leading manufacturers of API for anti-retroviral (ARV), oncology, cardiovascular, anti-diabetics, anti-asthma and gastroenterology.

With response to this development, the stock of Lauras Lab surged on the bourses. The stock which opened at Rs 430.50 jumped nearly seven per cent to touch an intraday high of Rs 457 apiece.